Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
European Journal of Immunology|March 20, 2025
ICAM-1 Is Overexpressed by Cancers and Negatively Impacts Antibody-Based Therapies Including Antibody-Drug ConjugatesJ Bradford Kline, Luigi Grasso, Nicholas C Nicolaides
Plos One|May 17, 2023
NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effectsNicholas C Nicolaides, J Bradford Kline, Luigi Grasso
Molecular Endocrinology (Baltimore, Md.)|September 28, 2002
Characterization of a novel and functional human prolactin receptor isoform (deltaS1PRLr) containing only one extracellular fibronectin-like domainJ Bradford Kline, Michael A Rycyzyn, Charles V Clevenger
European Journal of Immunology|May 5, 2023
NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε with improved cytotoxicity against humoral immunosuppressed tumorsLuigi Grasso, Qun Jiang, Raffit Hassan, et al.
Journal of Immunological Methods|September 29, 2016
Rapid high-throughput cloning and stable expression of antibodies in HEK293 cellsJared L Spidel, Benjamin Vaessen, Yin Yin Chan, et al.
European Journal of Immunology|August 26, 2018
Tumor-shed antigen CA125 blocks complement-mediated killing via suppression of C1q-antibody bindingJ Bradford Kline, Shawn Fernando, Erin N Ross, et al.
Bioconjugate Chemistry|August 19, 2017
Site-Specific Conjugation to Native and Engineered Lysines in Human Immunoglobulins by Microbial TransglutaminaseJared L Spidel, Benjamin Vaessen, Earl F Albone, et al.
Cancer Biology & Therapy|April 14, 2018
CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patientsNicholas C Nicolaides, Charles Schweizer, Elizabeth B Somers, et al.
Mabs|May 26, 2017
Engineering humanized antibody framework sequences for optimal site-specific conjugation of cytotoxinsJared L Spidel, Earl F Albone, Xin Cheng, et al.
Cytogenetic and Genome Research|October 18, 2017
FCGR2A and FCGR3A Genotypes Correlate with Farletuzumab Response in Patients with First-Relapsed Ovarian Cancer Exhibiting Low CA125Wenquan Wang, Elizabeth B Somers, Erin N Ross, et al.
Pageof 2